Oculis Holding AG Announces Registered Direct Offering

TL;DR

Oculis is selling 5M shares to investors on April 11th.

AI Summary

On April 11, 2024, Oculis Holding AG announced a registered direct offering to issue and sell 5,000,000 ordinary shares. The offering is being made to certain institutional and insider investors.

Why It Matters

This offering will provide Oculis with capital, potentially for further research and development or operational expansion.

Risk Assessment

Risk Level: medium — Direct offerings can dilute existing shareholders and signal a need for capital, but also provide funds for growth.

Key Numbers

• 5,000,000 — Ordinary Shares (Number of shares to be issued in the registered direct offering.)
• CHF 0.01 — Nominal Value per Share (The par value of each ordinary share being offered.)

Key Players & Entities

• Oculis Holding AG (company) — Registrant
• April 11, 2024 (date) — Date of Subscription Offers and Registered Direct Offering
• 5,000,000 (dollar_amount) — Number of ordinary shares to be issued
• CHF 0.01 (dollar_amount) — Nominal value per ordinary share

FAQ

Key Financial Figures

• $11.75 — purchase price of each Offered Share is $11.75. The gross proceeds to the Company from
• $59 m — fering are expected to be approximately $59 million, before deducting the offering ex

Filing Documents

• d748272d6k.htm (6-K) — 25KB
• d748272dex51.htm (EX-5.1) — 31KB
• d748272dex101.htm (EX-10.1) — 50KB
• d748272dex991.htm (EX-99.1) — 12KB
• g748272dsp0016.jpg (GRAPHIC) — 3KB
• g748272page07.jpg (GRAPHIC) — 5KB
• 0001193125-24-093243.txt ( ) — 132KB

Risk Factors

Risk Factors The Company is including the following risk factors in the prospectus supplement to be filed with the SEC: The dual listing of our ordinary shares may adversely affect the liquidity and value of those ordinary shares. Our ordinary shares are listed on the Nasdaq Global Market in the United States and we have submitted an application to begin the procedure for listing our ordinary shares for listing on the Nasdaq Iceland. The trading of our ordinary shares in these markets takes place in different currencies (U.S. dollars on Nasdaq US and Icelandic Krona on Nasdaq Iceland), at different times (resulting from different time zones, different trading days and different public holidays in the United States and Iceland) and with different settlement mechanics. The trading prices of ordinary shares on these two markets may differ due to these and other factors. Any decrease in the price of ordinary shares on Nasdaq Iceland could cause a decrease in the trading price of ordinary shares on Nasdaq US and vice versa. Investors could seek to sell or buy ordinary shares to take advantage of any price differences between the markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected volatility in both the trading prices on one exchange and ordinary shares available for trading on the other exchange. Further, the dual listing of ordinary shares may reduce the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for ordinary shares in the United States. The listing of ordinary shares on Nasdaq Iceland may result in increased additional compliance risk, which could have a material effect on our business, results of operations and financial condition, or may delay or discourage a takeover attempt. The Nasdaq Iceland Main Market is a regulated market in Iceland operated by Nasdaq Iceland, the Icelandic stock exchange. Issuers on Nasdaq Iceland Main Marke

Forward-Looking Statements

Forward-Looking Statements Any statements contained in this Report that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and are based on the Companys current beliefs and expectations. These forward-looking statements include statements regarding the Companys expectations on the closing of the Registered Direct Offering, the final approval of the Nasdaq Iceland Main Market listing application, expectations as to the first day of trading on the Nasdaq Iceland Main Market and expected cash balance after the Registered Direct Offering. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Offering and other risks and uncertainties that are described in the Risk Factors section of our Annual Report on Form 20-F filed with the SEC on March 19, 2024, and other filings we make with the SEC from time to time. Any forward-looking statements speak only as of the date of this Report and are based on information available to the Company as of the date of this Report, and the Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. EXHIBIT INDEX Exhibit Description 5.1 Opinion of Vischer AG, dated April 11, 2024 10.1 Form of Subscription Offer 99.1 Press

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OCULIS HOLDING AG Date: April 11, 2024 By: /s/ Sylvia Cheung Sylvia Cheung Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR